Myriad Genetics Acquires Precise Tumor, Precise Liquid And Laboratory From Intermountain Precision Genomics; Deal Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics has acquired Precise Tumor, Precise Liquid, and a laboratory from Intermountain Precision Genomics. The terms of the deal were not disclosed. The acquisition aims to enhance Myriad Genetics' oncology business, improve operational efficiencies, and create new clinical development opportunities. Myriad Genetics' CEO, Paul J. Diaz, expressed gratitude to Intermountain Healthcare for their role in advancing precision oncology care and looks forward to providing comprehensive genomic profiling to Intermountain Health System's patients and providers.
January 19, 2024 | 6:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics' acquisition of assets from Intermountain Precision Genomics is expected to strengthen its oncology business and create new opportunities for growth and efficiency.
The acquisition of Precise Tumor, Precise Liquid, and a laboratory is directly related to Myriad Genetics' core business and is likely to be viewed positively by investors. The deal is expected to bring operational efficiencies and new clinical development opportunities, which could lead to increased revenue and profitability in the short term. The lack of disclosed deal terms prevents a full assessment of the financial impact, but the strategic benefits suggest a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100